Effects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 Diabetes
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 110 participants.
Also called NCT01140893
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 110 participants
- Registry
-
NCT01140893
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- Not reported
- Countries
- France
- Registry status
- Unknown status
Technical summary
Registry record NCT01140893. Randomized; quadruple masking; primary purpose treatment. Start 2010-11 (registry gives no type); primary completion 2017-05 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 Diabetes
- Acronym
- EXEPUMP
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Exenatide
- Intervention (Drug)
- Placebo
- Lead sponsor
- University Hospital, Caen
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01140893- Content hash
497b3b203f946bfc1879ea690447ef2a0201a408e4d65e62f0f996802c11ebd5